A Prospective, Single-Arm, Multicenter, Phase II Clinical Study of Chidamide Combined With Ivonescimab in the Treatment of Advanced Non-Small Cell Lung Cancer With Acquired Resistance to Immunotherapy and High YAP Protein Expression
Latest Information Update: 03 Mar 2026
At a glance
- Drugs Ivonescimab (Primary) ; Tucidinostat (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 03 Mar 2026 New trial record